Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

Analysis of Revenues

Microsoft Excel

Revenues as Reported

Johnson & Johnson, income statement, revenues

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 29, 2019
Innovative Medicine 54,759 67,516 66,715 59,625 56,096
MedTech 30,400 27,427 27,060 22,959 25,963
Sales to customers 85,159 94,943 93,775 82,584 82,059

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).

Item Description The company
Sales to customers Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Johnson & Johnson sales to customers increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.